Action of glucagon-like peptide-1 (GLP-1) in humans.
ESC The ESC guidelines recommend the use of GLP-1 RAs in overweight or obese patients with T2DM to promote weight reduction (Class IIa, LoE B)
What data or evidence do we need to get these discoveries from bench to bedside faster, while prioritizing safety, efficacy, and effectiveness? - Alexa Woodward, PhD, Senior Director of Strategic Accounts at HealthVerity Nearly every major manufacturer is investing in obesity pipelines, including combination therapies that target multiple pathways
Tirzepatide dosing considerations for migraine-prone individuals Migraine-prone people are not the same as the general population when it comes to medication side effects
These signs may show that your dosage might need to be changed or checked, which is even more important for older adults or those who already have heart problems
The FDA-approved labels for these medications clearly list gastrointestinal adverse reactions as among the most frequently reported, with nausea being the most common, followed by vomiting, diarrhea, constipation, and abdominal pain
